|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Nabriva Therapeutics AG (NBRV) |
|
|
$0.39 0.00 (0.00%) as of 4:30 Wed 12/2
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
150,780,000 |
| Market
Cap: |
59.38(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.3938 - $0.3938 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Nabriva Therapeutics is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company engaged in the research, development and commercialization of anti-infective agents to treat serious infections. Co. has approval from the U.S. Food and Drug Administration for XENLETA for the treatment of adults with community-acquired bacterial pneumonia. XENLETA is an oral and intravenous treatment in the pleuromutilin class of antibiotics available for the systematic administration in humans. Co.'s CONTEPO is a potentially epoxide antibiotic for intravenous use in the U.S. for complicated urinary tract infections. Co. may develop XENLETA and CONTEPO for additional indications.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
51,839 |
| Total Sell Value |
$0 |
$0 |
$0 |
$9,588 |
| Total People Sold |
0 |
0 |
0 |
6 |
| Total Sell Transactions |
0 |
0 |
0 |
6 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gelone Steven P. |
President and COO |
• – – |
2020-11-30 |
4 |
D |
$0.43 |
$268 |
D/D |
(628) |
357,926 |
|
- |
|
| Sender Gary |
Chief Financial Officer |
• – – |
2020-11-30 |
4 |
D |
$0.43 |
$133 |
D/D |
(312) |
205,728 |
|
- |
|
| Crotty Robert |
Gen Counsel & Corp Secretary |
• – – |
2020-11-30 |
4 |
D |
$0.43 |
$157 |
D/D |
(368) |
203,444 |
|
- |
|
| Schranz Jennifer |
Chief Medical Officer |
• – – |
2020-11-30 |
4 |
D |
$0.43 |
$129 |
D/D |
(301) |
167,240 |
|
- |
|
| Crotty Robert |
Gen Counsel & Corp Secretary |
• – – |
2020-10-31 |
4 |
D |
$0.50 |
$181 |
D/D |
(366) |
203,812 |
|
- |
|
| Schranz Jennifer |
Chief Medical Officer |
• – – |
2020-10-31 |
4 |
D |
$0.50 |
$149 |
D/D |
(301) |
167,541 |
|
- |
|
| Sender Gary |
Chief Financial Officer |
• – – |
2020-10-31 |
4 |
D |
$0.50 |
$155 |
D/D |
(312) |
206,040 |
|
- |
|
| Schroeder Theodore R |
Chief Executive Officer |
• • – |
2020-10-31 |
4 |
D |
$0.50 |
$600 |
D/D |
(1,211) |
647,607 |
|
- |
|
| Gelone Steven P. |
President and COO |
• – – |
2020-10-31 |
4 |
D |
$0.50 |
$311 |
D/D |
(628) |
358,554 |
|
- |
|
| Lavino Francesco Maria |
Chief Commercial Officer |
• – – |
2020-09-30 |
4 |
D |
$0.53 |
$195 |
D/D |
(366) |
185,393 |
|
- |
|
| Crotty Robert |
Gen Counsel & Corp Secretary |
• – – |
2020-09-30 |
4 |
D |
$0.53 |
$195 |
D/D |
(366) |
204,178 |
|
- |
|
| Sender Gary |
Chief Financial Officer |
• – – |
2020-09-30 |
4 |
D |
$0.53 |
$166 |
D/D |
(312) |
206,352 |
|
- |
|
| Gelone Steven P. |
President and COO |
• – – |
2020-09-30 |
4 |
D |
$0.53 |
$335 |
D/D |
(628) |
359,182 |
|
- |
|
| Schranz Jennifer |
Chief Medical Officer |
• – – |
2020-09-30 |
4 |
D |
$0.53 |
$160 |
D/D |
(301) |
167,842 |
|
- |
|
| Schroeder Theodore R |
Chief Executive Officer |
• • – |
2020-09-30 |
4 |
D |
$0.53 |
$645 |
D/D |
(1,211) |
648,818 |
|
- |
|
| Lavino Francesco Maria |
Chief Commercial Officer |
• – – |
2020-08-31 |
4 |
D |
$0.62 |
$227 |
D/D |
(366) |
185,759 |
|
- |
|
| Sender Gary |
Chief Financial Officer |
• – – |
2020-08-31 |
4 |
D |
$0.62 |
$193 |
D/D |
(312) |
206,664 |
|
- |
|
| Crotty Robert |
Gen Counsel & Corp Secretary |
• – – |
2020-08-31 |
4 |
D |
$0.62 |
$227 |
D/D |
(366) |
204,544 |
|
- |
|
| Schroeder Theodore R |
Chief Executive Officer |
• • – |
2020-08-31 |
4 |
D |
$0.62 |
$750 |
D/D |
(1,211) |
650,029 |
|
- |
|
| Gelone Steven P. |
President and COO |
• – – |
2020-08-31 |
4 |
D |
$0.62 |
$389 |
D/D |
(628) |
359,810 |
|
- |
|
| Schranz Jennifer |
Chief Medical Officer |
• – – |
2020-08-31 |
4 |
D |
$0.62 |
$186 |
D/D |
(301) |
168,143 |
|
- |
|
| Lavino Francesco Maria |
Chief Commercial Officer |
• – – |
2020-08-20 |
4 |
D |
$0.65 |
$2,434 |
D/D |
(3,759) |
186,125 |
|
- |
|
| Broom Colin Md |
Director |
– • – |
2020-08-20 |
4 |
S |
$0.65 |
$7,165 |
D/D |
(11,064) |
248,936 |
|
39% |
|
| Crotty Robert |
Gen Counsel & Corp Secretary |
• – – |
2020-08-20 |
4 |
D |
$0.65 |
$2,434 |
D/D |
(3,759) |
204,910 |
|
- |
|
| Gelone Steven P. |
President and COO |
• – – |
2020-08-20 |
4 |
D |
$0.65 |
$5,026 |
D/D |
(7,761) |
360,438 |
|
- |
|
323 Records found
|
|
Page 7 of 13 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
